Research Compendium/Wolverine Stack
Stacks & FormulasResearch OnlyNot For Human Consumption

Wolverine Stack

TB-500 + BPC-157 Hybrid · Wolverine Recovery Stack

The gold standard recovery stack - BPC-157 and TB-500 combined in a single pen or vial for synergistic tissue repair and healing acceleration.

MECHANISM OF ACTION

The Wolverine Stack combines BPC-157 and TB-500 in a single formulation. BPC-157 brings localised healing: tendon-to-bone repair, angiogenesis via VEGFR2, GI cytoprotection, and GABAergic CNS modulation. TB-500 adds systemic reach: actin sequestration for broader tissue migration signals, cardiac progenitor cell activation, and anti-inflammatory cytokine modulation. Research shows the combination produces additive - potentially synergistic - tissue repair responses: TB-500's systemic cell migration combined with BPC-157's local vascularisation creates a comprehensive repair environment. Available in vial, pen, and nasal spray formats.

RESEARCH APPLICATIONS

  • Comprehensive tendon, ligament, and muscle injury recovery
  • Post-surgical tissue repair research
  • Systemic + local healing model (TB-500 systemic + BPC-157 local)
  • GI repair with systemic anti-inflammatory support
  • Athletic recovery and soft tissue research

RESEARCH HIGHLIGHTS

Synergistic Mechanism Evidence

Independent studies on each component show complementary mechanisms - TB-500 mobilises progenitor cells systemically while BPC-157 creates the angiogenic scaffold for integration at the injury site.

Ref: Multiple preclinical studies (see BPC-157 and TB-500 individual pages)

RESEARCH PROTOCOL NOTES

Typical blend ratioBPC-157 : TB-500 - 1:1 to 1:2 by weight in most commercial formats
Available formatsVial (5–20mg), Pen (Wolverine Hybrid Pen - Noventra, iPharma, BodyPharm, VMed Nasal Spray)
Research advantageCombined vial avoids two separate reconstitutions; co-administration timing no longer a variable

Chemical Identity

Storage & Stability

-20°C lyophilised. Reconstituted: 2–8°C, 21 days. Same storage rules as component peptides - the blend does not reduce stability.

Regulatory Status

Combined research compound. Same regulatory status as each component. Not WADA listed individually; TB-500 (Tβ4) is WADA S2 prohibited.

Back to Research CompendiumView Research Compounds →